Synchronous endometrial and ovarian carcinoma (SEOC): case series and literature review

Objectives: Synchronous endometrial and ovarian cancer (SEOC) is a rare female reproductive malignancy comprising ovarian and endometrial cancer. Precise diagnosis is crucial for treatment and prognostication, as overall outcome and treatment is differ from those of metastatic endometrial cancer (EC) or ovarian cancer (OC). In this review based on 4 case series of SEOC, we aim to discuss the clinical characteristic, accurate diagnosis using advance molecular analysis techniques and immunohistochemistry (IHC) tests and treatment modalities of SEOC. Method: Case series and literature review. Results: In our report, SEOCs are more prevalent in young premenopausal women with obesity, nulliparous and hereditary predisposition as risk factors. Abnormal menses, abdominal distention and abdominal pain were the common presenting symptoms. It made all diagnosis for SEOCs histologically based on established criteria. Surgery remains the main treatment modality with the goal for treatment and achieving diagnosis. All of our patients had an endometroid type histology with early stage and low grade histology for both endometrial carcinoma (EC) and ovarian carcinoma (OC) except two patients had concomitant seromucinous ovarian carcinoma (OC). We perform a review of the literature highlighting the characteristic and management of SEOC, particularly emphasizing the importance of IHC test on the histological confirmatory diagnosis and molecular studies. Conclusion: It is very essential to gain an accurate diagnosis, treat and prognosticate this disease as overall outcome and treatment is different compared to metastatic EC or OC.

Endometrial cancer (EC); Ovarian cancer (OC); SEOC; Metastatic disease; Outcome; Synchronous primary cancer

[1] Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. Journal of the National Cancer Institute. 2016; 108: djv428.

[2] Schultheis AM, Ng CKY, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. Journal of the National Cancer Institute. 2015; 108: djv427.

[3] Ayhan A, Yalçin T, Tuncer ZS, Gürgan T, Küçükali T. Synchronous primary malignancies of the female genital tract. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1992; 45: 63–66.

[4] Makris GM, Manousopoulou G, Battista MJ, Salloum I, Chrelias G, Chrelias C. Synchronous endometrial and ovarian carcinoma: a case series. Case Reports in Oncology. 2017; 10: 732–736.

[5] Yoneoka Y, Yoshida H, Ishikawa M, Shimizu H, Uehara T, Murakami T, et al. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma. Journal of Gynecologic Oncology. 2019; 30: e7–e7.

[6] Liu Y, Li J, Jin H, Lu Y, Lu X. Clinicopathological characteristics of patients with synchronous primary endometrial and ovarian cancers: a review of 43 cases. Oncology Letters. 2013; 5: 267–270.

[7] AlHilli MM, Dowdy SC, Weaver AL, St. Sauver JL, Keeney GL, Mariani A, et al. Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecologic Oncology. 2012; 125: 109–113.

[8] Dogan A, Schultheis B, Rezniczek GA, Hilal Z, Cetin C, Häusler G, et al. Synchronous endometrial and ovarian cancer in young women: case report and review of the literature. Anticancer Research. 2017; 37: 969–978.

[9] Sadidi H, Izadi-Mood N, Sarmadi S, Yarandi F, Amini-Moghaddam S, Esfahani F, et al. Comparison of clinicopathologic variables in coexistence cancers of the endometrium and ovary: a review of 55 cases in an academic center in Iran. Journal of Research in Medical Sciences. 2015; 20: 727–732.

[10] Devi YS, Singh LJ, Lalrindiki C, Jena AK, Mohanty S. Synchronous primary endometrioid type endometrial & ovarian adenocarcinoma; a rare case report. Journal of Medical Science and Clinical Research. 2018; 6: 994–997.

[11] Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas-a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecologic Oncology. 2001; 83: 355–362.

[12] Matsuo K, Machida H, Frimer M, Marcus JZ, Pejovic T, Roman LD, et al. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. Gynecologic Oncology. 2017; 147: 558–564.

[13] Dizon DS, Birrer MJ. Making a difference: distinguishing two primaries from metastasis in synchronous tumors of the ovary and uterus. Journal of the National Cancer Institute. 2015; 108: djv442.

[14] Wang T, Zhang X, Lu Z, Wang J, Hua K. Comparison and analysis of the clinicopathological features of SCEO and ECOM. Journal of Ovarian Research. 2019; 12: 10.

[15] Akriti DA, Asha DGN. A rare presentation of synchronous primary endometrial and ovarian cancer. International Journal of Clinical Obstetrics and Gynaecology. 2020; 4: 161–163.

[16] Chao A, Wu RC, Jung SM, Lee YS, Chen SJ, Lu YL, et al. Im- plication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology. Gynecologic Oncology. 2016; 143: 60–67.

[17] Wang Y, Wang Y, Li J, Yuan Z, Yuan B, Zhang T, et al. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. Journal of Hematology & Oncology. 2013; 6: 60.

[18] Zhan X, Li L, Wu M, Lang J. The prognosis of stage IA syn- chronous endometrial endometrioid and ovarian carcinomas. Archives of Gynecology and Obstetrics. 2019; 300: 1045–1052.

[19] Kim MK, Song SY, Do I, Kim S, Choi CH, Kim T, et al. Synchronous gynecologic malignancy and preliminary results of Lynch syndrome. Journal of Gynecologic Oncology. 2011; 22: 233.

[20] Takeda T, Banno K, Yanokura M, Anko M, Kobayashi A, Sera A, et al. Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: a case report. Molecular and Clinical Oncology. 2018; 9: 479–484.